Ethanol is widely used in pharmaceutical formulations as a solvent, preservative, and processing aid. Its multifunctional role makes it one of the most critical excipients in terms of quality control. However, when ethanol is sourced from non-GMP suppliers, it introduces significant vulnerabilities into the pharmaceutical value chain.
Risks to Patient Safety
Non-GMP ethanol may contain impurities such as aldehydes, higher alcohols or residual processing chemicals. These contaminants can directly compromise patient safety, particularly in oral liquids, injectables, and paediatric medicines where ethanol is present in measurable quantities.
- Documented tragedies, including the recent Gambia and Uzbekistan cough syrup incidents in 2022, highlight how contamination in excipients can lead to hundreds of patient injuries and deaths
- Even when acute harm is avoided, variability in ethanol purity can undermine formulation integrity, stability, and efficacy, resulting in variable patient outcomes
Risks to Manufacturing Operations
Industrial-grade ethanol is produced in very large volumes for fuel and chemical applications, where variability in water content and trace impurities may be tolerated. If used in pharmaceutical manufacture, this variability can lead to:
- Batch rejections due to out-of-specification testing results
- Process inconsistencies, such as crystallisation failures during API purification
- Increased production costs from rework, delays, and scrapped products
Risks to Regulatory Compliance
Global regulators (MHRA, EMA, FDA) expect excipient suppliers to demonstrate control of their production to GMP or equivalent standards. Failure to ensure this exposes manufacturers to:
- Inspection findings (e.g., FDA Form 483 observations) for inadequate supplier qualification
- Import alerts or warning letters if excipient traceability cannot be demonstrated
- Stricter audit requirements, increasing compliance costs and incurring reputational damage
The Wider Impact of Non-GMP Ethanol
Unlike APIs, which are tightly controlled, excipients are sometimes treated as commodities. The widespread use of ethanol as a solvent, preservative and processing aid means that lapses in quality control can ripple across multiple formulations, magnifying the risk. A single excipient failure can impact multiple products, brands, and patient groups simultaneously.
Non-GMP ethanol is not a cost-saving alternative; it is a high-risk vulnerability. For manufacturers, the risks span patient safety, operational performance and regulatory compliance.
The evidence is clear: to eliminate these risks, ethanol intended for pharmaceutical use must be sourced from GMP- or EXCiPACT GMP-certified suppliers. This is the only way to ensure consistent quality, protect patients and maintain the trust that underpins the pharmaceutical industry.
At Kimia, we understand the importance of purity, traceability and trust. Discover how our EXCiPACT GMP-certified ethanol and other pharmaceutical-grade solvents can minimise risk to operations, regulatory compliance and, most importantly, patient safety.
Learn more about Kimia’s pharmaceutical solutions here.
